Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cornichon family AMPA receptor auxiliary protein 3 (CNIH3)
- Target
- CNIH3
- Molecular classification
- Auxiliary subunit of ionotropic glutamate receptor complex, Channel regulator, Transmembrane protein, Other (COPII cargo receptor family)
01
Overview
Cornichon family AMPA receptor auxiliary protein 3 (CNIH3) is a transmembrane protein that acts as an auxiliary subunit of AMPA-type ionotropic glutamate receptors (AMPARs). CNIH3 regulates AMPAR trafficking and modulates their gating properties, influencing channel activation, deactivation, and desensitization rates, thus playing a crucial role in excitatory synaptic transmission in the brain. It promotes proper localization and maturation of AMPAR complexes and acts as a channel regulator, while also potentially participating in protein trafficking via the COPII vesicular pathway. CNIH3 has been implicated in disorders such as schizophrenia and opioid dependence, underlining its role in neuropsychiatric disease mechanisms. While it is a critical regulator of AMPAR function, no drugs currently target it directly, and it is not established as a clinical biomarker or therapeutic target at present.
- Other names
- Cornichon homolog 3CNIH-3Protein cornichon homolog 3FLJ38993Cornichon-3 protein
02
Mechanism of action
Not applicable for direct drugs, but CNIH3 modulates AMPA receptor function by: - Regulating receptor trafficking to the plasma membrane and synapse - Modulating activation/deactivation/desensitization kinetics
03
Biological functions
Regulation of AMPA receptor traffickingRegulation of synaptic receptor localizationModulation of AMPA receptor gating (affecting activation, deactivation, desensitization)Regulation of excitatory synaptic transmissionPromotes tetramerization and maturation of AMPA receptors
04
Disease associations
SchizophreniaOpioid abuse/dependenceNeuropsychiatric diseases (evidence from genetic and functional studies)
05
Safety considerations
No direct safety concerns reported related to targeting CNIH3Theoretical risks may include altered synaptic transmission or excitatory/inhibitory balance in the CNS if function is disrupted
06
Interacting drugs
None known (no direct small molecule or biologic modulators identified as of current data; interaction is primarily with endogenous AMPA receptors)
07
Biomarkers
None established as a clinical biomarker as of current data (potential research interest in synaptic function or neuropsychiatric conditions)
Beyond the preview
Go deeper on Cornichon family AMPA receptor auxiliary protein 3 (CNIH3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cornichon family AMPA receptor auxiliary protein 3 (CNIH3).